GlassScriptPhysician profile
Sara Kovaly
NPI 1730729773
$2,464.38
in general payments reported to CMS, 2019-2025
34 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.89 · 2022: $251 · 2023: $131 · 2024: $197 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331 · Long Term Medical Supply Or Device Loan: $698 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.37 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $122.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $847.86 | 2025 | |
| Merck Sharp & Dohme LLC | $183.20 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Cti Biopharma Corp. | $124.16 | 2022 | |
| Daiichi Sankyo INC. | $112.54 | 2022-2025 | Enhertu |
| Pfizer INC. | $101.19 | 2025 | |
| Gilead Sciences, INC. | $99.95 | 2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $97.00 | 2021-2025 | Opdivo, Opdualag |
| Abbvie INC. | $96.96 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $91.52 | 2024-2025 | Monoferric, Cosela |
| Taiho Oncology, INC. | $60.62 | 2024-2025 | |
| Celgene Corporation | $59.64 | 2022-2025 | Reblozyl |
| Eisai INC. | $55.76 | 2025 | |
| Pharmaessentia USA Corporation | $51.70 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $43.20 | 2024-2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $38.58 | 2024-2025 | Vivimusta, Danziten |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.64 | 2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $35.28 | 2025 | Tagrisso |
| Janssen Biotech, INC. | $32.32 | 2025 | Rybrevant, Tecvayli |
| Seagen INC. | $27.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.79 | 2025 | |
| Beone Medicines USA, INC. | $23.05 | 2025 | Brukinsa |
| Caris Mpi, INC. | $22.32 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $19.74 | 2025 | Itovebi |
| Sobi, INC | $18.98 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.86 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Ipsen Biopharmaceuticals, INC | $18.56 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $16.84 | 2023 | Alunbrig |
| Incyte Corporation | $16.31 | 2021 | |
| Puma Biotechnology, INC. | $16.00 | 2023 | |
| Adc Therapeutics America, INC. | $15.87 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.05 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2022 | |
| Emd Serono, INC. | $14.47 | 2025 | |
| Astellas Pharma US INC | $14.38 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Kovaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.